Korean J Med.
2009 Aug;77(Suppl 1):S188-S191.
Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. shlee119@snu.ac.kr
Abstract
- Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
MeSH Terms
-
Aged
Benzamides
Carcinoma, Renal Cell
Diarrhea
Fatigue
Female
Gastrointestinal Stromal Tumors
Hand-Foot Syndrome
Humans
Hypertension
Indoles
Nausea
Piperazines
Posterior Leukoencephalopathy Syndrome
Protein-Tyrosine Kinases
Pyrimidines
Pyrroles
Rifampin
Stomatitis
Imatinib Mesylate
Benzamides
Indoles
Piperazines
Protein-Tyrosine Kinases
Pyrimidines
Pyrroles
Rifampin
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reversible Posterior Leukoencephalopathy Syndrome(RPLS): with special reference to Brain MRA
- A Case of Posterior Reversible Leukoencephalopathy Syndrome Following Poststreptococcal Glomerulonephritis
- Cyclosporine-Induced Posterior Reversible Leukoencephalopathy Syndrome With Reduced Cerebral Perfusion
- A Case of Reversible Posterior Leukoencephalopathy Syndrome associated with Low dose Intravenous Immunoglobulin Therapy after Induction Chemotherapy in Acute Myeloid Leukemia
- RE: Comments on "Unilateral Reversible Posterior Leukoencephalopathy Syndrome after Coiling of an Aneurysm": The Authors Respond
